Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | RRM1 | P23921 | 1/20 | 0.31 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 2/20 | 0.30 |
| ▸ | HTR2C | P28335 | 2/20 | 0.30 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12295184 | 0.84 | MET (0.37) | HTR2AHTR2C | |
| SCHEMBL3097748 | 0.83 | CHRM2 (0.32) | CHRM2CHRM1RRM1RRM2B | |
| SCHEMBL5256194 | 0.83 | P2RX7 (0.33) | — | |
| SCHEMBL10381407 | 0.83 | MET (0.35) | CYP3A4ACHELMNAHTR2AHTR2C | |
| SCHEMBL12967883 | 0.81 | LMNA (0.34) | CYP3A4LMNA | |
| SCHEMBL12985905 | 0.77 | LMNA (0.35) | CYP3A4CHRM1LMNA | |
| SCHEMBL10304822 | 0.77 | ACHE (0.33) | ACHELMNA | |
| SCHEMBL9945905 | 0.77 | ACHE (0.33) | ACHELMNA | |
| SCHEMBL9945902 | 0.77 | CHRM2 (0.34) | ACHECHRM2CHRM1RRM1RRM2B | |
| SCHEMBL20314908 | 0.77 | MAPK1 (0.38) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352343-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210380588-A1 | Novel Compounds and Uses Thereof | OXFORD FINANCE LLC | 2021-12-09 | — | — | US | disclosed |
| US-10954244-B2 | Compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200299272-A1 | Urea Derivatives and Uses Thereof | KALA BIO, Inc. | 2020-09-24 | — | — | US | disclosed |
| US-10723719-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200157106-A1 | Novel Compounds and Uses Thereof | KALA BIO, Inc. | 2020-05-21 | — | — | US | disclosed |
| US-20190284172-A1 | Urea Derivatives and Uses Thereof | KALA BIO, Inc. | 2019-09-19 | — | — | US | disclosed |
| US-10351570-B2 | Compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-10329280-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-10316022-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-8563541-B2 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| US-8486950-B2 | Janus kinase inhibitor compounds and methods | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-16 | — | — | US | disclosed |
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20120329782-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120329782-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION (US) | 2012-12-27 | — | — | US | disclosed |
| WO-2011113802-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | WO | disclosed |
| WO-2010142752-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-20090197869-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION, A DELAWARE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TYK2, IRAK1, IRAK4 | CYP3A4 858/4885ACHE 4063/4885CHRM2 489/4885 |
| US-20120329782-A1 | AZEPINE INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | CYP3A4 3714/4885ACHE 4715/4885CHRM2 4874/4885 |
| US-10316022-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | CYP3A4 2435/4885ACHE 824/4885CHRM2 1040/4885 |
| US-11352343-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | CYP3A4 2435/4885ACHE 824/4885CHRM2 1040/4885 |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | CYP3A4 591/4885ACHE 4775/4885CHRM2 3929/4885 |
| US-20210380588-A1 | Novel Compounds and Uses Thereof | RB1, VEGFA, UACA | CYP3A4 1967/4885ACHE 1450/4885CHRM2 726/4885 |
| US-20200157106-A1 | Novel Compounds and Uses Thereof | RB1, VEGFA, UACA | CYP3A4 1967/4885ACHE 1450/4885CHRM2 726/4885 |
| US-10954244-B2 | Compounds and uses thereof | RB1, VEGFA, FLT4 | CYP3A4 1908/4885ACHE 1639/4885CHRM2 1081/4885 |
| US-10723719-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | CYP3A4 2435/4885ACHE 824/4885CHRM2 1040/4885 |
| US-20200299272-A1 | Urea Derivatives and Uses Thereof | UACA, RB1, FLT1 | CYP3A4 2435/4885ACHE 824/4885CHRM2 1040/4885 |
| US-10329280-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | CYP3A4 2435/4885ACHE 824/4885CHRM2 1040/4885 |
| US-20190284172-A1 | Urea Derivatives and Uses Thereof | UACA, RB1, FLT1 | CYP3A4 2435/4885ACHE 824/4885CHRM2 1040/4885 |
| US-10351570-B2 | Compounds and uses thereof | RB1, VEGFA, FLT4 | CYP3A4 1908/4885ACHE 1639/4885CHRM2 1081/4885 |
| US-20090197869-A1 | AZEPINE INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | CYP3A4 3714/4885ACHE 4715/4885CHRM2 4874/4885 |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | JAK1, JAK3, JAK2 | CYP3A4 3714/4885ACHE 4715/4885CHRM2 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.